Search

Your search keyword '"Nicosia, Santo V"' showing total 402 results
Start Over Author "Nicosia, Santo V"
402 results on '"Nicosia, Santo V"'

12. Biopathology of Ovarian Mesothelium

Author

Nicosia, Santo V., Saunders, Beatriz O., Acevedo-Duncan, Mildred E., Setrakian, Sebouh, Degregorio, Richard, Motta, P. M., editor, Familiari, Giuseppe, editor, Makabe, Sayoko, editor, and Motta, Pietro M., editor

Published
1991
Full Text
View/download PDF

20. Cytology of human ovarian surface epithelial brushings

Author

Nicosia, Santo V., Wilbanks, George D., Saunders, Beatrice, Mayer, James, Cardosi, Richard J., Kruk, Patricia A., Cheng, Jin, Bai, Wenlong, Coppola, Domenico, and Fiorica, James

Subjects
Ovarian cancer -- Research, Cytology -- Research, Health
Published
2004

34. Effects of raloxifene in a guinea pig model of leiomyomas

Author

Porter, Kathy B., Tsibris, John C.M., Porter, Gregory W., Fuchs-Young, Robin, Nicosia, Santo V., O'Brien, William F., and Spellacy, William N.

Subjects
Uterine fibroids -- Physiological aspects, Leiomyoma, Raloxifene -- Physiological aspects, Estradiol -- Physiological aspects, Health
Abstract

Raloxifene reduces the size of leiomyomas in estradiol-exposed guinea pigs. Leiomyomas are fibroid tumors of the uterus, and they can develop from continuous high levels of estrogen in the body. Researchers placed estradiol-secreting implants in guinea pigs to induce leiomyoma formation, removed the implants, then replaced them. Some animals also received raloxifene, an estrogen blocking drug. The tumors grew in the presence of estradiol, regressed without estrogen stimulation, and regressed with simultaneous estradiol and raloxifene treatment. Leiomyomas appear to require estradiol exposure to continue growing, and raloxifene appears to block this process.

Published
1998

36. Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation

Author

Anderson Nicole S, Turner Leslie, Livingston Sandra, Chen Ren, Nicosia Santo V, and Kruk Patricia A

Subjects
Gynecology and obstetrics, RG1-991
Abstract

Abstract Background Ovarian cancer is the most lethal gynecologic malignancy. The ovarian tumor microenvironment is comprised of tumor cells, surrounding stroma, and circulating lymphocytes, an important component of the immune response, in tumors. Previous reports have shown that the anti-apoptotic protein Bcl-2 is overexpressed in many solid neoplasms, including ovarian cancers, and contributes to neoplastic transformation and drug-resistant disease, resulting in poor clinical outcome. Likewise, studies indicate improved clinical outcome with increased presence of lymphocytes. Therefore, we sought to examine Bcl-2 expression in normal, benign, and cancerous ovarian tissues to determine the potential relationship between epithelial and stromal Bcl-2 expression in conjunction with the presence of lymphocytes for epithelial ovarian tumor progression. Methods Ovarian tissue sections were classified as normal (n = 2), benign (n = 17) or cancerous (n = 28) and immunohistochemically stained for Bcl-2. Bcl-2 expression was assessed according to cellular localization, extent, and intensity of staining. The number of lymphocyte nests as well as the number of lymphocytes within these nests was counted. Results While Bcl-2 staining remained cytoplasmic, both percent and intensity of epithelial and stromal Bcl-2 staining decreased with tumor progression. Further, the number of lymphocyte nests dramatically increased with tumor progression. Conclusion The data suggest alterations in Bcl-2 expression and lymphocyte infiltration correlate with epithelial ovarian cancer progression. Consequently, Bcl-2 expression and lymphocyte status may be important for prognostic outcome or useful targets for therapeutic intervention.

Published
2009
Full Text
View/download PDF

38. Argyrophilic nucleolar organizer regions in breast carcinoma: correlation with DNA flow cytometry, histopathology, and lymph node status

Author

Mourad, Walid A., Erkman-Balis, Bayzar, Livingston, Sandra, Shoukri, Mohamed, Cox, Charles E., Nicosia, Santo V., and Rowlands, David T., Jr.

Subjects
Tumor markers, Breast cancer -- Development and progression, Cancer -- Histopathology, Flow cytometry -- Diagnostic use, Health
Abstract

Argyrophilic nucleolar organizer regions (AgNOR) have been correlated with proliferative activity of neoplasms. Increased AgNOR may reflect increased proliferative activity of cells or ploidy. To explore this hypothesis, 41 breast carcinomas were processed for AgNOR silver staining and DNA flow cytometry. AgNOR counts were expressed as mean AgNOR/nucleus and percentage of tumor cells with more than five AgNOR/nucleus. The first count was designated mean AgNOR or mAgNOR, and the second count was designated AgNOR proliferative index or pAgNOR. Using Mantel-Haensel statistical analysis, carcinomas that exhibited mAgNOR of 2.4 or more had a high likelihood of aneuploidy (P < 0.0001), an S-phase fraction of more than 5.8% (P < 0.003), or a diameter greater than 2 cm (P < 0.007). In addition, tumors with pAgNOR of 8% or more showed a statistically significant correlation with aneuploidy (P < 0.004), tumor grade (P < 0.04), and a more significant one with high S-phase fraction (P < 0.0001). No significant correlation was obtained between pAgNOR and tumor size or lymph node status. These data indicate that AgNOR quantitation reflects changes in DNA ploidy and cell proliferation. They also suggest that the mean AgNOR counts correlate best with the DNA mass or ploidy and that the frequency of cells with higher AgNOR count best reflects proliferative activity or S-phase fraction. Cancer 1992; 69:1739-1744.

Published
1992

Catalog

Books, media, physical & digital resources
See catalog results